One-year antibody persistence and safety of a 4-dose schedule of MenACWY-CRM in healthy infants from South Korea.
Hoan-Jong LeeDae Sun JoYun Kyung KimHyunju LeeKyung Hyo KimDokyung LeeCarlo CurinaMarco CostantiniSilvia BarbiYan MiaoMichele PellegriniPublished in: Clinical and experimental vaccine research (2019)
Antibody persistence (hSBA/rSBA titers ≥8) was determined in 39%-99% of children 1 year after a 4-dose MenACWY-CRM series during infancy, with an acceptable clinical safety profile.